











































Molecular patterns in acute pancreatitis reflect generalisable
endotypes of the host response to systemic injury in humans
Citation for published version:
Neyton, LPA, Zheng, X, Skouras, C, Doeschl-Wilson, A, Gutmann, M, Uings, IJ, Rao, FV, Nicolas, A,
Marshall, C, Wilson, L-M, Baillie, K & Mole, D 2020, 'Molecular patterns in acute pancreatitis reflect
generalisable endotypes of the host response to systemic injury in humans', Annals of Surgery, vol. n/a, no.
n/a, n/a. https://doi.org/10.1097/SLA.0000000000003974
Digital Object Identifier (DOI):
10.1097/SLA.0000000000003974
Link:






Author's peer reviewed manuscript as accepted for publication.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 17. Aug. 2021
 
  
Molecular patterns in acute pancreatitis reflect generalisable endotypes of 
the host response to systemic injury in humans. 
 
Authors 
Lucile P. A. Neyton1,2#, Xiaozhong Zheng1, Christos Skouras3, Andrea Doeschl-Wilson2, Michael 
U. Gutmann4, Iain Uings5, Francesco V. Rao6, Armel Nicolas6, Craig Marshall7, Lisa-Marie 
Wilson7, J. Kenneth Baillie2*# and Damian J. Mole1,3*#. 
 
Affiliations 
1Medical Research Council Centre for Inflammation Research, Queen’s Medical Research 
Institute, The University of Edinburgh, Edinburgh, UK 
2Division of Genetics and Genomics, The Roslin Institute, The University of Edinburgh, 
Edinburgh, UK 
3Clinical Surgery, School of Clinical Sciences and Community Health, The University of 
Edinburgh, Edinburgh, UK 
4School of Informatics, The University of Edinburgh, Edinburgh, UK 
5GSK Discovery Partnerships with Academia, Exploratory Discovery, Future Pipeline Discovery, 
Medicines Research Centre, Gunnels Wood Road, Stevenage, UK. 
6DC Biosciences Limited, James Lindsay Place, Dundee Technopole, Dundee, UK 
 
  
7Department of Laboratory Medicine, NHS Lothian, Edinburgh, UK.  
* indicates joint senior authors 
# indicates corresponding authors 
 
Corresponding authors 
j.k.baillie@ed.ac.uk; damian.mole@ed.ac.uk  
Keywords 









Objective: Acute Pancreatitis (AP) is sudden onset pancreas inflammation that causes systemic 
injury with a wide and markedly heterogeneous range of clinical consequences. Here, we 
hypothesised that this observed clinical diversity corresponds to diversity in molecular subtypes 
that can be identified in clinical and multi-omics data.  
Summary Background data: Observational cohort study. n=57 for the discovery cohort (clinical, 
transcriptomics, proteomics and metabolomics data) and n=312 for the validation cohort (clinical 
and metabolomics data). 
Methods: We integrated co-incident transcriptomics, proteomics, and metabolomics data at serial 
time points between admission to hospital and up to 48 hours after recruitment from a cohort of 
patients presenting with acute pancreatitis. We systematically evaluated four different metrics for 
patient similarity using unbiased mathematical, biological and clinical measures of internal and 
external validity. 
We next compared the AP molecular endotypes with previous descriptions of endotypes in a 
critically ill population with acute respiratory distress syndrome (ARDS). 
Results: Our results identify four distinct and stable AP molecular endotypes. We validated our 
findings in a second independent cohort of patients with AP.  
We observed that two endotypes in AP recapitulate disease endotypes previously reported in 
ARDS.  
Conclusions: Our results show that molecular endotypes exist in AP and reflect biological patterns 
that are also present in ARDS, suggesting that generalisable patterns exist in diverse presentations 









AP is defined as acute inflammation of the pancreas(1) and has a worldwide incidence of 
34 per 100,000 person-years(2). It is the commonest gastrointestinal cause for emergency hospital 
admission(3). Inflammatory damage to pancreatic acinar cells initiates an inflammatory cascade 
mediated by damage-associated molecular patterns, alarmins, inflammatory cytokines, metabolites 
and other soluble and cellular mediators of inflammation that propagate inflammation locally in 
the pancreas, and cause extrapancreatic organ dysfunction in the lungs, kidney, liver and other 
body systems, together resulting in multiple organ dysfunction syndrome (MODS)(4, 5). MODS 
occurs in 1 in 4 individuals who develop AP and is accompanied by deregulation of cardiovascular, 
autonomic nervous and immune system homeostasis(6), leading to death in one fifth of those with 
AP-MODS(7). Despite this currently accepted unifying disease model, clinical patterns of AP are 
markedly heterogeneous and severity is not directly proportional to the amount of pancreas damage 
on radiological imaging(8, 9). AP is caused by a wide range of precipitants, including 
choledocholithiasis, excess ingestion of alcohol, trauma, pancreatic manipulation at endoscopy, 
viral infections, certain venoms and specific prescription medicines(6). Currently, the 
clinicopathological paradigm in AP is convergent: diverse etiologies converge onto acinar cell 
damage, and the resulting systemic inflammatory response is stratified as mild, moderate or severe. 
In common with other types of systemic injury(10-16), we hypothesized the existence of molecular 
subtypes in AP, designated as endotypes(17). We predict that detailed knowledge of those 
endotypes will have clinical and therapeutic relevance(18). As new medicines for AP emerge, the 
existence of endotypes will become critical to directing treatment choices and understanding 








The methodology to tackle this problem, particularly using time-series multi-omics data, 
is not settled. We designed a systematic, data-driven evaluation of four different metrics to 
quantify dissimilarity between patients and cluster them accordingly. 
 
Materials and Methods 
Data acquisition 
We used samples and data from the IMOFAP (Inflammation, Metabolism and Organ Failure in 
AP) cohort(19) (n=79 recruited participants) as our discovery set and samples and data from n=312 
patients from the KAPVAL (Kynurenine pathway in AP, VALidation) cohort, as the validation set 
(full details of the sampling and cohorts in Supplementary Materials and Methods).  
AP diagnosis was confirmed for 57 out of 79 recruited patients in IMOFAP according to 
the revised Atlanta criteria(20). Integrated multi-omics analysis excluded 3 patients who had a 
prolonged interval (>200 hours) after symptom onset and therefore were late in their disease 
trajectory to avoid bias (Figure 1a). The median time interval between symptom onset and 
recruitment was 21.3 hours (Q1-Q3 13.5-54.4 in hours). Multiple timed samples of peripheral 
venous blood were taken (Figure 1b). When analysing single time point data from time point 0, 
we selected 40 patients (22 mild, 14 moderate and 4 severe AP cases) based on whether they had 
a complete multi-omics dataset. When comparing time-series, we required at least two complete 
time points, therefore selecting 34 patients (16 mild, 13 moderate and 5 severe AP cases). The 
KAPVAL validation cohort included 312 participants (274 in ward care level, 7 admitted to a high-
dependency unit, and 31 to an intensive care unit) with confirmed AP and clinical data and serum 








  Data pre-processing is summarised in Supplementary Figure 1 and Supplementary 
Materials and Methods for transcriptomics, proteomics and metabolomics data. 
Data Analysis 
We considered and evaluated four data analysis strategies. We tested single time point-
based strategy using Euclidean distances and three time-series-based methods: 1) Area Under the 
Curve and PCA, 2) PCA with Trajectory(21) and 3) Dynamic Time Warping(22) (described in 
more detail in Supplementary Materials and Methods). For all methods, we used pre-processed 
Z-scores for the concatenated dataset (metabolomics, proteomics and transcriptomics) to take full 
advantage of the breadth of available measurements.  
Single time point Euclidean distances 
The first considered strategy consisted of computing Euclidean between all pairs of patients 
at multiple time points. This was performed for time point 0, 24 and 48 hours individually and 
obtained measures were used to quantify dissimilarity between individuals. 
AUC and PCA 
For each variable and individual we computed area under the curve (AUC) values for the 
corresponding time series using the trapezoidal rule (Supplementary Materials and Methods) 
and projected this new dataset onto Principal Component (PCA) space where, using the first two 
components, we computed Euclidean distances between individuals (Supplementary Materials 








Trajectory through PCA space 
Trajectories of patients through PCA space were used to cluster patients(21), projecting all 
time points onto a two-dimensional PCA space, using the first two components. To map the 
trajectory evolution through PCA space we considered the direction between pairwise time points 
for each individual using integer values between 1 and 4 and the Hamming distance(21) to evaluate 
the dissimilarities between individuals.  
Dynamic time warping 
Dynamic time-warping (DTW) (22) is an algorithm that aligns and compare time series, 
by warping the time axis, finding the best alignment and the distance between two transformed 
curves. We compared patients using DTW, considering all pre-processed variables and estimated 
distances between pairs of individuals. 
Clustering 
We sought to discover AP endotypes within these data, specifically seeking disease 
trajectory groupings. To achieve this, we applied unsupervised clustering to patient-to-patient 
distance matrices(23), and devised a systematic, data-driven evaluation of the results from the 
different methods. 
Using the dissimilarity matrices previously obtained we clustered them using hierarchical 
clustering and Ward’s method (Supplementary Materials and Methods).  
The number of clusters was chosen according to stability, computed by generating 100 
bootstrapped sets, clustering them and assessing the overlap with the original solution. Robustness  
of these clusters and the potential to be generalisable to other cohorts was estimated 









To perform the validation, we selected time point 0 values to mimic a realistic situation in 
which individuals would be allocated to a subgroup as early as possible in their disease trajectory. 
As bootstrapping with cluster comparisons produced a measure of stability, we used it to 
filter solutions based on a Jaccard index (JI) threshold of 0.75(24).  
Compound set enrichment analyses were carried out to assess biological plausibility. Our 
working model was: each clustering method is intended to detect real biological similarities among 
a group of patients, rather than chance groupings due to random noise. We predicted that a method 
that detects real similarities between patients is more likely to recapitulate known biological 
groupings that drive the clustering. KEGG(25) data was used to perform the enrichment and test 
subsets of compounds. Generalised linear models were generated for each compound to test 
whether they identified groups. Results for all compounds of a set were summarised and significant 
items (using a p-value threshold of .05) used to quantify biological relevance (Supplementary 
Materials and Methods) 
Enrichment 
Partial Least Square Discriminant Analysis (PLS-DA) was used to highlight biomarkers 
within each subgroup, weighted and used to compute Variable Importance in Projection (VIP) 
scores. Applying a threshold of 1, top variables were retained for the enrichment using Reactome 
data and Fisher's exact test (Supplementary Materials and Methods). 
Validation in an independent dataset 
To validate the subgroups, we used the KAPVAL cohort clinical data and metabolomes, 








we classified KAPVAL samples using PLS-DA models with 25 or less metabolite predictors 
(Supplementary Materials and Methods). Signals between IMOFAP and samples from the 
KAPVAL cohort allocated to these same groups were compared using metabolites not included in 
the models (369 metabolites). Additionally, we computed in-group proportions (IGP) and 
associated FDR-corrected p-values(28). Briefly, the IGP of an endotype is the proportion of 
samples allocated to that endotype having their nearest neighbour (determined using Pearson’s 
correlation coefficients) allocated to that same endotype. 
Comparison with another disease 
We compared our endotypes with ARDS endotypes described in another study(11). From 
ARDS endotypes we extracted variables rankings and compared it to rankings in each one of our 
endotypes. For each one of the two ARDS cohorts (ALVEOLI and ARMA), we compared the lists 
of ranked variables to each one of our endotypes using Spearman’s correlation coefficients and 
FDR-corrected p-values (Supplementary Materials and Methods).  
Comparison with an independent tool 
MOFA(29) highlights variables explaining variation between samples, using factor 
analysis. Model factors explaining less than 1% of the variance in all omics were dropped. We 
clustered individuals into a 4-cluster solution using two latent factors and compared MOFA to 
previously generated outputs.  
Results 









The biology of inflammation in AP is complex and, when the entire AP cohort is taken as 
a whole, is seemingly heterogeneous. In order to uncover otherwise hidden groupings within the 
overall patient group with AP, seeking similarity between individuals who are part of an apparently 
dissimilar larger group, we integrated transcriptomics, proteomics and metabolomics data to have 
a comprehensive view of the biological processes across these different systems layers(30). 
Because the majority of patients who develop AP-MODS are admitted to critical care within 48 
hours after presentation to hospital(7), we included time points between 0 and 48 hours after 
presentation (Figure 2b). We took an unsupervised approach to the statistical analysis, i.e. without 
preconceived notions of expected dominance of certain molecular mechanisms, and we initially 
included all variables that were available to us to avoid bias due to previous findings or hypotheses. 
After data pre-processing (Supplementary Figure 1), we created a combined dataset consisting 
of 651 metabolites, 371 proteins and 19766 genes that was used as input. The area under the curve 
combined with PCA, trajectory through PCA space and dynamic time warping methods required 
more than a time point per sample and thus 20 were discarded, resulting in 34 samples being 
analysed (5 severe, 13 moderate and 16 mild AP). Demographics are presented in Supplementary 
Table 1. 
To highlight subgroups of patients of potential interest, once dissimilarity matrices were 
obtained, hierarchical clustering with the agglomerative Ward’s method(31-33) was applied 









Next, to ensure that the groupings that we had discovered were robust and stable, in other 
words would not be drastically altered if one or two individuals or variables changed, we used the 
Jaccard Index (JI). The stability criterion (JI>0.75) was met by the AUC in PCA space method 
(JI=0.79) and state-space trajectories in PCA space (JI=0.76), demonstrating internally robust 
groups (Figure 1c and Supplementary Figure 2, Supplementary Tables 2 and 3) whose 
structure would be expected to be recovered using a different input set. 
Biological validity, or the number of known biological processes that were discretely 
identified by the clusterings, was strongest for the AUC in PCA space clustering method over 
alternatives, based on number of FANTOM5 and KEGG gene-based and KEGG metabolite-based 
hits (Figure 1c, Supplementary Table 4). We therefore took forward AUC in PCA space as the 
solution for external validation. 
Endotype characterisation 
 In order to explore the biological relevance of the discovered endotypes, and, also if 
maximum clinical utility is to be obtained from endotype assignation in AP, the endotype should 
be identifiable as close as possible to the time the affected individual seeks medical help.  
We identified each one of our four endotypes using capital letters, A (n=13), B (n=10), C 
(n=5) and D (n=6). Each identified top variable (Figure 2a), here either gene or metabolite, was 
cross-referenced with publicly available resources (Supplementary Table 5). More specifically, 
for endotype A, prominent features consisted of: N-acetyl-3-methylhistidine and N-acetyl-1-
methylhistidine – increased after muscle myofibrillar proteolysis and in renal failure(34); XIRP1 








and MAP3K6 – a mitogen-activated protein kinase kinase involved in apoptosis signalling(36). 
Endotype B defining features were: complement factor H-related protein; HOXD3 – upregulation 
of which increases immune cell adherence by upregulating glycoprotein IIb/IIIa(37); TRIM48 – 
integral to interferon-g signaling and oxidative stress-responsive cell death via apoptosis signal-
regulating kinase 1(38); PPP1R3A(39); and REG3A – which encodes a bactericidal C-type lectin 
known commonly as pancreatitis-associated protein that, among multiple actions, alters the gut 
microbiome and regulates gastrointestinal inflammation(40) (Fig 2a). Discernable features for 
endotype C include GGT2 (g-glutamyl transferase 2) – glutathione homeostasis; dopamine 
sulphate – a marker of increased gastrointestinal metabolism of endogenous dopamine(42); 
citrulline – integral to the tricarboxylic acid cycle; and SPTSSB – the rate-limiting enzyme for 
sphingolipid biosynthesis(43). For endotype D, the thematic features were CELA2A – pancreatic 
elastase 2; UDP-glucuronosyltransferase – which is associated with Gilbert-type 
hyperbilirubinemia(44, 45); and SLCO1B7 – a liver-specific organic anion transporter involved in 
bile secretion. 
The link of biological function to endotype was achieved by using baseline data and computing 
the variable importance in projection (VIP) scores using a PLS-DA applied to the AUC+PCA 4-
cluster grouping, as shown in Figure 2a, Supplementary Figures 3 and 4. Critically, although 
the PLS-DA model was built using data solely from baseline, the clusterings obtained using time=0 
data produced inferior results, with Jaccard indexes never exceeding 0.75 (Supplementary Figure 
5). This shows that a dynamic dimension is beneficial for training an illness trajectory model.  
To add further to the biological relevance of the endotypes, we also performed a compound 
set enrichment analysis for each endotype which highlighted processes of potential interest for 








 All participants with severe AP clustered in endotype A, despite data on clinical outcome 
being withheld from the model (Figure 2b), and this finding was statistically significant (severe 
vs. non-severe, Fisher’s exact test, P=.038). Furthermore, in-hospital death was reported for two 
patients, and both were allocated to endotype A, confirming endotype A to be associated to 
individuals at higher-risk of severe illness and/or death, although this association is not proven 
statistically, and will require further external validation.  Modified MODS score distributions for 
cardiovascular, renal and respiratory systems were represented and are available as 
Supplementary Figure 8. However, the etiology of AP was distributed evenly across endotypes 
(Fisher’s exact test, P=1) (Figure 2c). Gender (Fisher’s exact test, P= .67) or time of onset of 
symptoms (ANOVA, P=.97) were not statistically significantly associated with endotype 
(Supplementary Results). Independence between endotypes and systemic inflammatory response 
syndrome (SIRS) was tested for and was not rejected (SIRS vs no SIRS, Fisher’s exact test, 
P=.097) (Supplementary Figure 9).  
External validity 
 Having identified four endotypes in the discovery dataset, we wanted to see if that was 
reproducible in an independent dataset. Therefore, to externally validate the generalisability of our 
findings and confirm that the identified endotypes could also be detected in a distinct non-
overlapping cohort, we applied our analytical methods and our results in an independent dataset 
of AP patients, the KAPVAL cohort (Figure 3a and Supplementary Figures 10, Supplementary 
Tables 6 and 7). Independence between reported deaths and group allocation was not rejected 
(Fisher’s exact test, P=.39, Figure 3b). However, admission to critical care (ICU/HDU vs. ward 








We computed Spearman’s correlation (comparison of ranks, validated using a t-
distribution) for each pairwise comparison of groups from both cohorts, using metabolites that 
were not used to predict the group allocations (Supplementary Figure 11, Figure 3d). We 
obtained significant results when comparing groups from IMOFAP cohort to their corresponding 
groups in KAPVAL cohort (correlation coefficients ranged from 0.38 to 0.65, corresponding 
adjusted p-values <.001 for each endotype). This demonstrated underlying biological similarity 
between corresponding endotypes and was unlikely to be observed by chance.  
We computed IGP for all endotypes, using the recruitment time point, and obtained values 
of 0.73, 0.51, 0.64 and 0.63 respectively for endotypes A, B, C and D. Associated FDR-corrected 
p-values (using permuted centroids and 10 000 iterations) were <.001 for endotypes A and D and 
0.01 for endotypes B and C. This confirmed that endotypes identified in our IMOFAP cohort were 
also present in KAPVAL and could be identified using an early time point. 
Generalisability in ARDS 
We noticed an unexpected similarity between our endotypes and disease endotypes 
reported in a related but distinct condition, ARDS(11). Severe AP can cause ARDS, but there are 
multiple other causes of ARDS including sepsis, trauma, and major surgery(46). Importantly, only 
6 out 56 AP-confirmed patients (no measured value available for n=1) in our discovery cohort met 
the Berlin definition of ARDS(47) at recruitment. Specifically, 5 of them were included in our 
clustering analysis, 4 (P:F ratios 130.3, 223, 273 and 286 mmHg) of which were allocated to 
endotype A and 1 to endotype B (P:F ration 290 mmHg). We hypothesised that the AP endotype 
C reflects the disease phenotype 1 ARDS endotype reported by Calfee et al(11).  We found 19 
variables that matched the 31 variables in the ARDS study (8 physiological, 9 clinical biochemical, 








recruitment, in Supplementary Table 8). There was a significant negative correlation between 
endotype A with phenotype 1 in the two ARDS cohorts reported elsewhere (FDR-corrected p-
values, P=.046 for ALVEOLI and ARMA), when considering the variables in common. 
Interestingly, endotype C correlated positively with the ALVEOLI (P=.046) and ARMA cohorts 
(P=.046). (Figures 4a and 4b) using the same variables. This suggests that the endotypes of AP 
that we report here are generalisable to another type of critical illness. 
MOFA results 
Finally, we highlighted a substantial overlap (Jaccard index 0.88, Supplementary Figure 
12) between our proposed endotypes and groups highlighted using a multi-omics data integration 










Disease endotypes have been commonly described using one data type, in sepsis for 
example(12, 13, 15). However, there are advantages to using multi-omics datasets for 
endotyping(48, 49). Indeed, multi-omics-based analyses have the potential to uncover biomarkers 
and/or processes of interest that could not be highlighted using solely one omic layer(30). It is also 
possible to identify commonalities and discrepancies between different data types and explore new 
avenues for disease study. One limitation lies in the fact that adding more layers will increase the 
data dimensionality. Thus, dimensionality reduction and/or variable selection are worth 
considering when doing endotype discovery(30). It should also be noted that some data types might 
not be directly comparable and should be either homogenised or analysed separately using 
specialised frameworks taking into account these differences. 
 
Limitations 
In this study, we have clustered AP individuals using multi-omics profiles. Four clusters 
were identified using AUC values projected onto a 2D-PCA space. The clusters consisted of 13, 
10, 5 and 6 individuals, respectively for endotypes A, B, C and D. It should be noted that the 
presented solution might beneficiate from refinement using a larger cohort. Indeed, it is possible 
that some of the clusters could be further split into new clusters and/or new clusters identified, but 
not enough samples were available to do so. The identification of discriminating variables, which 








would also benefit from a larger cohort size. This would help in reducing the minimum number of 
variables required to confidently assign AP-affected individuals to one of the four clusters. 
When validating our endotypes, we used the KAPVAL cohort. One time point and 
metabolomics measurement were available. However, we identified similar signal within the 
KAPVAL cohort data, when compared to our four endotypes, highlighted using time-series multi-
omics data. This demonstrated that this common signal was not only driven by transcriptomics 
data, as it could have been expected due to the high number of gene variables. 
Conclusions 
Our data confirm the existence of pathobiological molecular-based endotypes in AP that 
do not clearly align with current clinical measures of severity or etiology. Using a novel serial 
evaluation approach with high-resolution multi-omics data, we systematically identify four 
endotypes that passed stability and biological relevance validation. These AP endotypes were 
validated in a second independent cohort. While it is premature to expect that identification of 
these specific endotypes will directly influence treatment decisions in AP today, in general, the 
discovery and identification of endotypes is likely to become important for future treatment choice 
and response to therapy in AP. Defining AP endotypes has permitted the identification of 
mechanisms and biomarkers of interest that could be targeted for the development of novel 
therapeutic strategies, and increase our understanding of AP. Allocating AP individuals to one of 
the endotypes could move the current paradigm towards a more personalised approach. Moreover, 
patients at higher risk, notably those allocated to endotype A, could be identified early in their 
disease trajectory, maximising their chance of a better outcome.  
Moreover, we observed a statistically significant similarity with endotypes previously 








(n=549 and n=473) cohorts of patients with a distinct clinical syndrome, ARDS. Despite the wide 
differences in methodology, our approach found the same signals (Figure 5).  
Our unsupervised, systematic analysis re-discovered these two ARDS endotypes in an 
almost completely non-overlapping clinical syndrome. We conclude that these patterns may reflect 
generalisable components of the host response to systemic injury. Future attempts to classify 
subtypes within critical illness syndromes, including sepsis, trauma, AP and ARDS should 
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Figure 1.  
a. Flow diagram for the IMOFAP cohort. Study flow chart for patient samples and data from 
the IMOFAP study included in the analysis showing filtering process and reasons for exclusion. 
After filtering, remaining samples (n=54) could be used for further analyses, however, some 
presented a single time point (n=20) and thus were not included in analyses requiring several 
samples over a time course. 
b. Sample and data time points. Samples used to generate data types and corresponding time 
points are represented. Time point 0 corresponds to recruitment time point (some clinical data was 
collected when a patient was admitted to the hospital and is represented at t=-5 hours on the figure). 
Dashed lines show the median time from admission to hospital to intensive care admission in those 
who required it (12 hours) and median time from admission to hospital to death for AP fatalities 
(82 hours)(7). 
c. AP endotypes discovery process. Data analysis overview using the 34 pre-selected IMOFAP 
individuals (individuals with less than 2 time points for one type of omics were not included in the 
analysis, n=20). Each row represents results for one of the three time-series-based method. Within 
the clustering section, hierarchical trees for each time series-based clustering method are presented 
along with the optimal solution (the optimal number of clusters and respective sample allocations 
being represented by branches colour), patient identifiers are reported on the x axis and distances 
are presented on the y axis. Stability measures are reported for all displayed solution (average 
Jaccard index) and a summary of the number of compound sets significantly enriched is shown for 
each category (respectively FANTOM5 results, gene-based results and metabolic compound 
 
  
results) in the evaluation section. Results based on a single time point (using Euclidean distances) 
were not presented here as the clusters obtained using these presented poor structure (generally a 
main group in which the majority of individuals clustered and a number of single-patient groups). 
For the selected solution (Area-under-the-curve combined with PCA), findings were reproduced 
using one AP cohort and compared to previously defined ARDS endotypes, as illustrated in the 
reproducibility section. 
 
Figure 2.   
a. AP endotypes. Heatmap of normalised and scaled variable values of the top 10 variables, 
averaged for all patients belonging to each endotype, for all four subgroups. Compound names, on 
the y axis, are reported in grey italic when corresponding to genes. Other compounds refer to 
metabolites. Group labels are reported on the bottom x and on the left y axis to highlight which 
variables correspond to which group. For visualisation purposes row values were scaled between 
0 and 1. Colours are representative of the range of values observed.  
b. Clinical severity distribution. For comparison purposes, distribution of clinical severity 
categorised by mMODS score within each endotype. For each one of the four endotypes, the 
number of patients in each severity category (mild, moderate or severe) is shown using a colour 
code. The x axis was used to represent the identified endotypes and the y axis to show the number 
of patients, per endotype, falling in each one of the severity categories.  
c. Etiology distribution.  Distribution of etiology within each endotype. For each endotype, the 
number of patients per unique etiology is shown. The x axis was used to represent the identified 





Figure 3.  
a. Allocation of KAPVAL samples to IMOFAP-based endotypes.  Schematics representing the 
process to assign KAPVAL individuals to endotypes identified in IMOFAP cohort. This is for 
illustrative purposes only, variables and values represented do not correspond to the models 
created or the data used to build them. After identifying metabolites in common between the 
IMOFAP and KAPVAL cohorts, one PLS-DA model per endotype is built, choosing a number of 
metabolites to include to maximise the prediction accuracy. The four obtained models are then 
used to predict allocations for all KAPVAL samples, returning a value for each. A sample will be 
allocated to a group given the model for which the largest PLS-DA predicted value was obtained 
(corresponding to the closest match for a given sample). 
b. In-hospital mortality for the KAPVAL cohort. Using predicted allocations for KAPVAL 
samples, distribution of in-hospital mortality within each endotype. 1 refers to death and 0 to no 
death. The x axis represents the allocation endotypes for KAPVAL samples and the y axis the 
number of patients, per allocation endotype, falling in each one of the mortality categories. 
c. Care level for the KAPVAL cohort.  Distribution of care level for KAPVAL individuals given 
endotype allocation. Three categories of care level were used (ward, HDU for high-dependency 
unit and ICU for intensive care unit) and correspond to the three represented colours. The x axis 
shows the allocation endotypes for KAPVAL samples and the y axis the number of patients, per 
allocation endotype, falling in each one of the care level categories. 
d. Internal validation of AP endotypes. Correlation matrix representing Spearman’s correlation 
results for pairwise comparisons between training (IMOFAP) and testing (KAPVAL) data. 
Spearman's correlation coefficients were computed using average values per variable per endotype 
 
  
for AUC-PCA-based four clusters in IMOFAP (x axis) and corresponding predicted KAPVAL 
endotypes (with allocated samples, on the y axis). Correlation coefficients are represented using a 
colour code, as described by the colour bar on the figure's right-hand side. FDR-adjusted p-values 
are reported for each cell. 
 
Figure 4.  
a. ALVEOLI/ARMA and IMOFAP cohorts comparison for endotypes A and C. Variable 
values available as part of the IMOFAP study that occur in common with those reported in the 
ARDS study of Calfee et al are compared. Ranks of normalised values (Z-scores) are represented 
for endotypes A and C against ranks from Calfee et al results for the ALVEOLI cohort (upper 
panel) and the ARMA cohort (lower panel). Linear trends are plotted along Spearman’s correlation 
coefficients (using reported variable ranks) and corresponding FDR-corrected p-values. 
b. Reproducibility of AP endotypes in two ARDS cohorts. Comparisons between ARDS cohorts 
(ALVEOLI and ARMA) and IMOFAP endotypes (A, B, C and D). Using matched variables, 
Spearman’s correlation coefficients between ranked variables from Calfee et al and average Z-
scores for the four AP endotypes were computed for all pairwise comparisons.  Colours represent 
correlation coefficients values and FDR-corrected p-values are reported within each cell for all 
pairwise comparisons. 
 
Figure 5.  
Endotype model. Systematic inflammatory endotypes model. Highlighted endotypes in AP 
patients are represented alongside their overlap with ARDS endotypes described in Calfee et al.  
The top part of the figure shows pancreas injury along with their potential initiators and 
 
  
corresponding endotypes. This is reproduced in the figure bottom part, for ARDS, representing 
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ID allantoin citrulline codeine orotate xylose
005 -0.306 -0.227 -0.122 -0.178 -0.137
ID group allantoin citrulline codeine orotate ribose serine xylose
5 3 -0.3062 -0.2266 -0.1218 -0.1779 -0.4771 -0.2121 -0.1371
14 3 -0.5530 -0.0453 0.9011 -0.1534 0.5191 -1.7056 0.1578
2 1 -0.3092 -0.1001 -0.1798 -0.3121 0.9146 0.2981 -0.2759
60 2 0.5028 -0.0453 -0.1798 -0.1056 -0.4270 -0.7262 0.1052
76 4 -0.2109 -0.2595 -0.1799 -0.0569 -0.3210 0.4076 -0.2451
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to accompany manuscript: Molecular patterns in acute pancreatitis reflect generalisable 
endotypes of the host response to systemic injury in humans, by Lucile P. A. Neyton, et al. 
 
Supplementary Materials and Methods 
Cohorts 
IMOFAP study details 
In brief, consecutive emergency attendees to hospital with sudden onset abdominal pain 
with nausea and/or vomiting, and a serum amylase value greater than 100 iU/L were identified 
using an automated laboratory alert system with clinical verification, at all times of day or night 
for a period of three months. Confirmation of the diagnosis of AP according to the revised 
Atlanta criteria(1) was made after recruitment in 57 of 79 recruited patients, all of them having 
developed AP before recruitment. Samples were aliquoted into specific tubes containing 
appropriate preservation solution for subsequent DNA and RNA extraction, or serum and 
plasma extracts were prepared after centrifugation and snap frozen and the cold chain 
maintained until acquisition.  
Although every effort was made to capture all time points, this was not always possible, 
and on occasion (for example, at the request of the patient to omit a short interval repeat 
venepuncture), time points were omitted. 
 
KAPVAL study details 
The KAPVAL cohort is a fully-linked anonymised biosample cohort which is made up 
of samples and data from all patients presenting to the Royal Infirmary of Edinburgh with a 
serum amylase level > 300 iU/L (3-fold above the upper limit of the reference range for our 
laboratory), clinically annotated and coded ad compliant with the revised Atlanta criteria(1) for 
the diagnosis of AP. An aliquot of gel-clot activator serum is retained and stored at -80 °C for 
all patient samples that have an elevated serum amylase. Using a linked anonymisation code, 
to which the investigators are blinded, the diagnosis of acute pancreatitis was confirmed by 
trained members of a specialist data collection team, using clinical and laboratory data obtained 
from the individuals electronic health record. The variables used in the analysis include age, 
gender, date and time of admission and discharge, diagnostic codes (3 levels), standard clinical 
biochemistry and clinical haematology tests, level of critical care, duration of critical care and 
mortality. Serum samples were used as described. 
Data acquisition 
Transcriptomics data acquisition 
2.5 ml of peripheral venous blood was collected into the PAXgene Blood RNA Tube (BD 
Biosciences) following the manufacturer’s instructions and stored at -80 °C until used. Total 
RNA was extracted and purified using the PAXgene Blood miRNA Kit (QIAGEN). The RNA 
integrity of total RNA samples was assessed using the Agilent 2100 Bioanalyzer. The mRNA 
in a total RNA sample was converted into a library of template molecules of known strand 
origin using the reagents provided in an Illumina® TruSeq® Stranded mRNA library prep 
workflow. The subsequent sequence data was obtained using Illumina HiSeq 4000 75PE 
system. 
 
Proteomics data acquisition 
Serum was obtained from peripheral venous blood by centrifugation and stored at -80 °C 
until used. Sera were subjected to depletion of abundant serum proteins using Proteome Purify 
12 Human Serum Protein Immunodepletion Resin (R&D Systems). Denaturing was followed 
by alkylation with N-ethylmaleimide and acetone precipitation. Digestion used lysyl 
endopeptidase (LysC) and trypsin before labelling with 10plex TMT reagents (Thermo Fisher 
Scientific). TMT-labelled peptides were fractionated into 4 fractions each by High-pH Reverse 
Phase chromatography then each fraction analysed by RPLC-MS/MS/MS (70 min linear 
gradient) on a Fusion Tribrid Orbitrap operating in Data Dependent Acquisition mode 
(MultiNotch Simultaneous Precursor Selection method; MS1: profile mode, Orbitrap 
resolution 120k, 375-1550 m/z, AGC target 200,000, 50 ms max. injection time, RF lens 60%; 
MS2: centroid mode, IonTrap, 12 dependent scans, 1.2 Th isolation window, charge states 2-
7, 60 s dynamic exclusion, CID fragmentation (35%, activation Q 0.25), AGC target 10,000, 
70 ms max. injection time; MS3: profile mode, 5 precursors, 2 Th isolation window, Orbitrap 
resolution 50k, 100-500 m/z, AGC target 50,000, 105 ms max. injection time, HCD 
fragmentation (60%)). Control samples were used as internal cross-channel controls in 
different TMT samples and in different TMT channels to avoid any specific bias. Raw files 
were searched with MaxQuant (version 1.5.7.4) against a human proteome obtained from 
UniProt, with the match-between-runs option selected to allow for transfer of peptide 
identifications between files. 
 
Metabolomics data acquisition 
Serum was obtained from peripheral venous blood by centrifugation and stored at -80 
°C until used. Aliquots of sera were shipped on dry ice to Metabolon Inc., 617 Davis Drive, 
Suite 400, Durham, NC 27713 USA. Serum samples underwent automated protein depletion 
using methanol (MicroLab STAR® system) followed by four fraction analysis by UPLC-
MS/MS with positive ion mode electrospray ionization, UPLC-MS/MS with negative ion mode 
electrospray ionization, LC polar platform and, GC-MS. QA/QC steps included: a pooled 
matrix sample as a technical replicate throughout, extracted water samples as process blanks, 
and a bespoke cocktail of QC standards spiked into every sample for instrument performance 
monitoring and chromatographic alignment. Instrument variability was determined by 
calculating the median relative standard deviation (RSD) for the standards.  Overall process 
variability was determined by calculating the median RSD for all endogenous metabolites (i.e. 
non-instrument standards) present in 100% of the pooled matrix samples. Ultrahigh 
Performance Liquid Chromatography-Tandem Mass Spectroscopy (UPLC-MS/MS):  The 
LC/MS portion of the platform used a Waters ACQUITY ultra-performance liquid 
chromatography (UPLC) and a Thermo Scientific Q-Exactive high resolution/accurate mass 
spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap 
mass analyser operated at 35,000 mass resolution. Gas Chromatography-Mass Spectroscopy 
(GC-MS):  The samples for GC-MS was derivatized under dried nitrogen using bistrimethyl-
silyltrifluoroacetamide and separated on a 5% diphenyl / 95% dimethyl polysiloxane fused 
silica column (20 m x 0.18 mm ID; 0.18 um film thickness) with helium as carrier gas and a 
temperature ramp from 60° to 340°C in a 17.5 min period and analysed on a Thermo-Finnigan 
Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron impact 
ionization (EI) and operated at unit mass resolving power. Data Extraction and Compound 
Identification:  Raw data were extracted, peak-identified and QC processed using Metabolon’s 
hardware and software and compounds were identified by comparison to library entries of 
purified standards or recurrent unknown entities. Metabolite Quantification and Data 
Normalization:  Peaks were quantified using area-under-the-curve.  Where runs spanned 
multiple days, a data normalization step was performed to correct variation resulting from 
instrument inter-day tuning differences. 
 
Data pre-processing 
Transcriptomics data pre-processing 
RNA-Seq data consisted of 75bp paired-end Illumina reads stored as FASTQ files. One 
batch was carried out using polyA selection and the other using rRNA depletion. Reads were 
filtered based on QC results (FASTQC v0.11.2) to trim low-quality ends using a phred 
threshold of 20 and discard resulting reads shorter than 25bp. Read alignment was performed 
against the genome assembly hg38 using  STAR(2) (v2.5.0a). Counts were generated as a 
proxy for gene expression by assigning previously aligned reads to exons using the tool 
featureCounts(3) (v1.5.2). hg38 genome was used as the reference genome. The difference in 
RNA sequencing (library preparation) was accounted for using a protein-coding only filter, a 
batch removal algorithm (using the ARSyNseq function from NOISeq R library(4)) and a 
normalisation step (FPKM). Finally, the normalised counts were transformed into Z-scores. 
This allowed a comparison across samples. PCA plots of the counts before and after batch 
effect removal are available in Supplementary Figure A. 
Supplementary Figure A. Batch effect correction for RNA-Seq data. PCA plots before and 
after batch effect removal. RNA-Seq counts values obtained using featureCounts, for coding 
genes only, are represented in the left figure. The same counts, after batch effect correction and 
FPKM normalisation are represented in the right figure. We chose to represent the top two 
principal components (PC1 on the x axis and PC2 on the y axis) in terms of represented 
variance (as reported on the corresponding axes). Batches are represented using defined colours 
and shapes, as presented in the legend element. 
 
Proteomics data pre-processing 
After raw data acquisition and initial processing to generate intensity-based values, any 























































































































































































































































were applied using the minimum value for each compound, as any missing value would suggest 
a value below the detection limit. As samples from similar batches grouped together when 
performing the clustering step, we corrected for it with ComBat, using a parametric empirical 
Bayes framework, to remove the irrelevant variation between samples due to the different runs 
carried out.  Measurements were then transformed into Z-scores.  
 
Metabolomics data pre-processing 
Metabolomics data consisted of an abundance list (raw ion counts). Data were pre-
processed using a similar pipeline as the one used for the proteomics data but did not require a 
batch effect removal step. Data from the KAPVAL cohort was pre-processed in the same way. 
 
Data analysis 
Analyses were carried out using Python (version 3.5) and R (version 3.3.2). Libraries 
used include dtwclust in R and numpy, pandas, rpy2, scipy, sklearn, statsmodels in Python.  
The total starting data set consisted of the relative expression of a normalised set of 
19766 genes, integrated with 1383 protein and 686 metabolite abundances. After data pre-
processing, the dataset consisted of 651 metabolites, 371 proteins and 19766 genes. 
 
Distance metrics and clustering 
Area Under the Curve and PCA 
Each time series was summarised by computing its AUC value, a single value 
representing the cumulative magnitude of response over time and computed using the 
trapezoidal rule (based on linear interpolation by interval). Consequently, values obtained for 
each variable could be treated as independent from others. We normalized the values based on 
the time difference between the first and last included time points. Using this new dataset we 
projected the values in a principal component analysis space where, selecting the first two 
components, we computed Euclidean distances between the different individuals. The 
Euclidean distances were weighted according to the proportion of variance explained by each 
principal component. PCA is a method of choice when encountering high dimensionality data 
(because of its dimensionality reduction ability), as much for data visualization as for data 
analysis, and is hypothesis free(5). Indeed, PCA is only sensitive to the correlation structure in 
the data and does not make specific assumptions related to the stratification of the input data. 
 
Trajectory through PCA space 
As described in another study(6), trajectories of patients through selected components 
can be helpful when clustering patients. Here we projected all time points of each individual 
onto a two-dimensional PCA space and looked at their evolution through this newly defined 
space. To characterize the trajectory of an individual through this space we considered the 
direction taken between each pair of time points for these particular patients. We coded this 
direction with a value of 1, 2, 3 or 4 depending on the direction taken when dividing the space 
into four quadrants. This was repeated for all patients and eventually a vector of directions was 
obtained for each patient.  
The Hamming distance was used to compare the vectors. When taking two vectors of the same 
length, the Hamming distance is computed by counting, in an element-wise fashion, the number 
of different elements. The values were then used as dissimilarity measures between patients. 
This allowed to combine the advantages of PCA and trajectory analysis.  
 
Dynamic time warping 
Computation of distances between patients using dynamic time warping was carried 
out using the dtwclust package in R. The algorithm then considers each pair of samples. More 
specifically, for each variable, a matrix is generated and reports the difference in magnitude 
between all possible pairs of time points. One matrix of dimensions (time series 1 length*time 
series 2 length) is obtained for each variable. A summary matrix is generated for each patient 
by summing the individual matrices associated to each variable, element-by-element. The 
warping consists of finding a trajectory in that matrix that will minimize the distance between 
the two series. The process will start from the matrix element corresponding to the first points 
of the two series being compared (in other terms the first element of the summary matrix) and 
will end when reaching the last series points (corresponding to the last element of the matrix). 
As this is performed on a summarized matrix, the selected warping represents a consensus 
alignment minimizing the summed differences in magnitude between the two multivariate 
time-series. From this warping a final distance is calculated and can be used as a dissimilarity 
value. We performed linear imputation on time series when time points were not equally spaced 
or missing. It was preferred as it allowed a fairer comparison when dealing with time series of 
different lengths/sampling pattern. 
 
Clustering 
Clustering, allowing to group individuals from a cohort, was performed using hierarchical 
clustering and Ward’s method. Ward’s method is an agglomerative method and works by 
minimizing distances within each group. Although it is usually used for Euclidean related 
distances (which is not the case for all the presented methods) it has been used successfully for 
other types of distance(7-9) and produced the best results here when compared with others (in 
terms of validation results). The number of clusters was chosen according to the stability of 
each solution. For all number of clusters ranging from two to twenty we assessed this using 
bootstrapping combined with the Jaccard index. For a chosen number of clusters k we replaced 
individuals from the initial cohort to create a new input dataset. It was then used to re-perform 
the clustering 100 times. Each one of the new results obtained was compared to the initial 
solution given k clusters. Each cluster from the k generated clusters was compared to the most 
similar cluster of the initial solution. The Jaccard index computed the overlap between the two 
and this was averaged for all matched groups that were part of a solution. After 100 repetitions 
we obtained a value for each k number of clusters by taking the average of the averaged Jaccard 
indexes and the solution with the highest value was chosen as the best one. Twenty was chosen 
as the maximum number as any greater value would have resulted in many clusters composed 
of one or very few individuals. This was not desirable as very little information could have 
been drawn from it. Additionally, we chose not to select for further analyses any solution with 
one group or more presenting less than three individuals. 
 
Validation 
Number of clusters and stability 
For all number of clusters ranging from two to twenty we assessed stability using 
bootstrapping combined with the Jaccard index, as defined in the previous section.  
 
Biological plausibility 
Compound identifiers were converted when necessary using R package biomaRt. Data 
used consisted of KEGG(10) pathways extracted from R package GAGE(11) when analysing 
gene and protein data and from MetaboAnalystR(12) when analysing metabolites. As four 
groups were identified, the aim was to assess whether or not a subset of compounds 
(corresponding to a pathway) was associated with the group label. For each pathway this was 
tested using generalised linear models. A model was fitted to the data for each compound of a 
corresponding pathway with the group label being the fixed effect and the response variable 
being the values associated to this gene. To assess the effect of the group on the values, we 
performed a likelihood test to compare the newly created model to a null model, returning a 
single p-value. Using Stouffer’s method to combine p-values, we computed a single p-value 
per pathway. For elements of a pathway, individual p-values were given a weight 
corresponding to the inverse of the total number of pathways a gene was involved in. This, this 
prevented overlapping pathways from biasing our results. R function anova with test="LRT" 
was used to do the tests. As the gene sets tested for enrichment were the same for each one of 
the three methods tested to cluster individuals, p-values were used to quantify the biological 
relevance of a clustering. Each compound set with an associated value under the threshold of 
.05 was counted as differentially expressed and counts obtained for each method were 
compared to determine the most biologically relevant result. FANTOM5(13, 14)  co-
expression clusters were used to compare cell type gene signatures with our groups and thus 
allowing the discovery of closely involved cell types. The same strategy was applied to 
determine if a compound set was significantly enriched or not, using the same 5% cut-off. 
Results were used as a way to quantify the biological pertinence, have an overall look at the 
results and select clustering solutions. 
 
Enrichment analysis 
Partial Least Square Discriminant Analysis (PLS-DA) is a classification algorithm. 
PLS-DA models were used to select variables for the enrichment analysis. Given group labels 
it will project the data onto a new space, given a number of components selected by the user, 
and then rotate the components to maximize the separation between samples of different 
groups. Finally, weights can be extracted and a correlation with each variable computed.  This 
is called Variable Importance in Projection and the higher the value the more the variable will 
have contributed to the classifier model.  We filtered variables deemed significant for the 
classification task  using a VIP threshold value of 1(15) for each one of the models. The lists 
were then used to perform compound set enrichment analysis.  
To analyse the list produced for each group we first generated a Reactome database 
using files freely available from the Reactome website (https://reactome.org/download-data, 
lowest level pathway files). As our variables were of different type (transcriptomics, 
proteomics and metabolomics) we generated a merged pathway list using different Reactome 
files. Pathways were then selected for analysis if they had 10 or more compounds and no more 
than 500 as they were deemed neither robust nor informative. We then used Fisher’s exact test 
to obtain a p-value per pathway based on the number of matches present in our list and the total 
number of compounds considered initially to be included in the list of interest. For each list p-
values obtained from this test were then corrected using an FDR based strategy and represented 
applying a threshold of .001. Following the same strategy, time points 24 and 48 were also 
analysed and results added alongside the ones obtained for time point 0. 
 
Validation in an independent dataset 
PLS-DA models with 3 components were created for each one of the IMOFAP group 
but using solely metabolites that were available for the KAPVAL cohort as well. VIP scores 
were computed and a threshold of 25 variables was set as a maximum of features to be included 
in each model. An optimal number of variables between 3 and 25 was selected based on 
maximum accuracy values.  
To determine allocations for the KAPVAL cohort we applied each one of the PLS-DA 
models to all KAPVAL individual and allocated them to the group from which they were the 
closest to.  
To compare the biology between the groups of the two cohorts we computed average 
values per variable per group and compared them between the cohorts as inspired by Sweeney 
and al.(16). We only compared metabolites that were not included in the PLS-DA models used 
to classify KAPVAL individuals (369 metabolites). To perform the comparison between 
average values we computed Spearman’s correlation (comparison of ranks, p-values computed 
using a t-distribution) for each pairwise comparison of groups from both cohorts. Z-score 
values for the IMOFAP cohort and for KAPVAL allocated samples can be visualised at 
http://baillielab.net/pancreatitis/validation (username: pancreas and password: review). 
 
Comparison with an external dataset 
 To compare obtained endotypes with external data, ARDS endotypes definitions(17) 
were selected. Matched variables between the IMOFAP and chosen ARDS datasets were 
compared using variable ranks and Spearman’s correlation coefficients.  
When computing Spearman’s correlation coefficients and associated p-values for, we used the 
statsmodels and scipy modules in Python.  
Supplementary Results 
Clustering results 
For the AUC+PCA method, the total percentage of variance explained by the first two 
components used was 51.5%, comprising 40.2% for PC1 and 11.3% for PC2. For this four-
group solution, the silhouette score(18) based on the distance matrix was 0.39 (range 0.23 to 
0.57). 
Moreover, we generated a clustering for the AUC combined with PCA method using 
the residuals from a linear model which included gender, age and time of onset. The 4-cluster 
solution obtained using the corrected data was compared to the chosen partition and showed a 
high level of similarity (JI = 0.82 and distance matrices correlation, using a Mantel test, showed 
a correlation of 0.91 with an associated p-value of .01). 
Based on PLS-DA results, for all compounds with a VIP associated value greater or 
equal to 2 averaged time profiles and AUC values can be obtained via an online page that can 
be accessed through the following address: http://baillielab.net/pancreatitis/, username: 
pancreas and password: review) along with some clinical and cytokine measures (filtered 
variables based on ANOVA results and a threshold of .05).   
It is interesting to note that correlation between distance matrices obtained using only 
one type of omics and the complete distance matrix (as used to highlight the presented clusters), 
using Mantel test, suggest that most of the signal can be attributed to transcriptomics data 
(correlation value equal to 1, FDR-corrected p-value <.001). Moreover, the correlation 
coefficient between the metabolomics-based distance matrix and the complete distance matrix 
shows a value of 0.22 (FDR-corrected p-value 0.03), suggesting some contribution. 
Length of stay varied between the groups with the reported values of endotype A 
globally higher when compared to others (median values were 5.9, 5.1, 4.5 and 5.3 days 
respectively, for each group with corresponding Q1-Q3 3.2-12.8, 2.8-10.8, 2.5-9.7 and 3.3-7.8, 
in days Supplementary Figure B). 
 
Supplementary figure B. Length of stay for the KAPVAL cohort. Box plot of length of 
hospital stay (in days) per identified endotype for KAPVAL allocated samples. The bars 
represent 95% confidence intervals and the central bar depicts the median value. The x axis 
shows endotypes to which KAPVAL samples were allocated (A, B, C and D) and the y axis, 
the length of stay for each one of the allocated samples, in days. 
 
External validity 
We also noticed a great difference in structure between our endotypes and the ones 
highlighted using MOFA when applied to baseline KAPVAL data (Jaccard index 0.22, 
Supplementary Figure C), confirming that baseline data alone cannot be used directly to 
highlight the structure of AP endotypes and that previous knowledge of patient trajectories is 
required to generate the endotype models. However, once established the models could be 
applied to presentation data without the further need to collect several time points. 
 
Supplementary figure C. MOFA tools results compared to highlighted clusters with 
KAPVAL cohort data. Using KAPVAL metabolite data and selecting a 4-cluster solution, 
comparison of results. KAPVAL samples were allocated to the four endotypes identified (using 
AUC combined with PCA) and as illustrated in Figure 3a. Colours indicate the results of the 
allocation obtained using PLS-DA models and shapes show MOFAtools results when choosing 
four clusters and two latent factors. Values of KAPVAL samples on the latent factors are 





































































































































Supplementary Figure 1. Pre-processing summary. For metabolomics (panel a), proteomics 
(panel b) and transcriptomics (panel c), an overview of the pre-processing steps presented in 

























































































Alignment & Quantification 












processed in a very similar way. A filtering was applied to discard variables with 90% or more 
missing values. This was followed by an imputation step using variables minimum value, as a 
missing value indicates a value below the detection limit. To remove the batch effect present 
in the proteomics data, ComBat was used. For both metabolomics and proteomics, a Z-score 
scaling was applied and was followed by linear interpolation. Quality control was done for raw 
transcriptomics data (using FASTQC results to trim reads with low ends using a phred 
threshold of 20 and discard reads shorter than 25 bp). Alignment and quantification using 
respectively STAR and featureCounts was performed and was followed by FPKM-
normalisation. As with metabolomics and proteomics data, Z-score scaling and linear 



























Supplementary figure 2. Overlap between the different clustering solutions. For the 
optimum clustering (AUC+PCA-based, consisting of 4 clusters), comparison with other four-
group solutions obtained using the two other main methods (Trajectory and DTW). Average 
Jaccard Index (JI) values (one value is computed for each of the four groups) are reported for 
each comparison to assess the overlap. Numbers within the circles correspond to numbers of 
individuals.  Group matching (to determine which group of the first method should be 
compared to a group of the second method) between two methods was performed by trying all 
possible pairwise combinations and choosing the one producing the highest average Jaccard 
index. For any A vs B comparison, blue sections correspond to the number of cluster elements 
in common between solutions A and B. Orange and white sections refer to cluster elements not 
in common but respectively part of solution A and B. DTW refers to dynamic time warping, 
AUC+PCA to area-under-the-curve combined to principal component analysis and trajectory 





















Supplementary figure 3. PLS-DA top variables for each identified endotype. The top 10 
variables from the four PLS-DA models (for clusters A, B, C and D) are presented. Top 
variables were extracted based on VIP (Variable Importance in Projection) values. Names on 
the y axis refer to gene (in grey italic) or metabolite compounds. Values reported on the x axis 
are VIP values and are computed using correlation values between PLS-DA components and 







Supplementary figure 4. AP endotypes overview for VIP-selected variables. Heatmap of 
normalised and scaled variable values of the top 10 variables (as reported in Supplementary 
figure 3), for each identified group. Compound names, on the y axis, are reported in grey italic 
when corresponding to genes, all others refer to metabolites. Patient identifiers are reported on 
the bottom x axis and colours represent endotype allocations on the top x axis. For visualisation 
purposes row values were scaled between 0 and 1. Colours are representative of the range of 




Supplementary figure 5. Hierarchical clustering result for time point 0 data. Using only 
time 0 data and choosing two as an arbitrary number of clusters, dendrogram based on 
Euclidean distances and Ward’s algorithm. Patient identifiers are reported on the x axis and 












































































































































Supplementary figure 6. Time profiles per group for selected variables. Time series 
generated from average Z-score value per time point per group identified using our AUC-PCA 
strategy. Imputed values (using linear imputation and 3-hour intervals) were used to generate 
the plots.  The top 2 variables per group were selected from PLS-DA results using VIP scores 
and consisted of 5 genes and 3 metabolites. The average Z-score values per time point are 
represented using the y axis. Points represent sampling times. The x axis shows time in hours 
and curves were obtained using Cardinal splines. Graphs were produced with 
http://baillielab.net/pancreatitis/ (username: pancreas and password: review, graphs generated 





























































Supplementary figure 7. Enrichment results. Significant pathway terms (filtered using an 
adjusted p-value threshold of 0.01%) from enrichment results for each identified group based 
on variables lists selected using VIP scores. For the enrichment analysis we selected variables 
with a VIP score value equal to or greater than 1, based on PLS-DA models. Pathway data was 
fetched from the Reactome pathway database. Time point 0 was selected for assessment and 
all data types were included (metabolites, proteins and genes). Results for time points 24 and 
48 hours are reported as well.  Fisher’s test was used to generate p-values. Pathway full names 
are reported in the figure. Columns represent results for one endotype at a selected time point. 
A coloured cell represents a significant value and a white cell a non-significant value (based 
on FDR-adjusted p-values). 
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Supplementary figure 8. Modified MODS distribution per endotype. For each one of the 
four endotypes, the number of patients in each modified MODS category (respectively 
cardiovascular, renal and respiratory) is shown using a colour code. Patients were categorised 
in two classes, as described in the figure’s legend. A value of 1 was given to any patient having 
a modified MODS greater than one at time point 0. A value of 0 was given otherwise. nan 
represents a missing value. The x axis was used to represent the identified endotypes and the y 





Supplementary figure 9. SIRS distribution per endotype. For each one of the four 
endotypes, the number of patients in each SIRS (Systemic Inflammatory Response Syndrome) 
category is shown using a colour code. Patients were categorised in three classes, as described 
in the figure’s legend, corresponding respectively to SIRS persisting for 48 or less consecutive 
hours, SIRS persisting for more than 48 hours and no reported SIRS. The x axis was used to 
represent the identified endotypes and the y axis to show the number of patients, per endotype, 







Supplementary figure 10. Flow diagram for the KAPVAL cohort.  Study flow chart for 
patient samples and data from the KAPVAL study included in the analysis showing cohort 
structure. Individuals were-prefiltered for hyperamylasemia and thus all 312 individuals were 
kept for the analysis. As opposed to the IMOFAP cohort, symptoms onset time was not 
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Supplementary figure 11. PLS-DA predicted values for each identified endotype. PLS-
DA predicted values distribution plots for all four identified endotype. When building the 
models, a value of 1 is assigned to the current endotype and a value of -1 to all others. For each 
endotype, distribution of predicted values, as returned by the PLS-DA procedure, for assigned 
(represented in blue, assignment to the best matching group) and unassigned KAPVAL 
individuals (depicted in pink) are represented. Kernel density estimates are fitted for both 










Supplementary figure 12. MOFA tools results compared to highlighted clusters with 
IMOFAP cohort data.  Comparison of MOFAtools results with AUC+PCA-derived clusters. 
AUC values were used as input (to be consistent with the AUC+PCA strategy) and a 4-cluster 
solution was extracted from MOFA results using the first two latent features (LF1 and LF2). 
Colours are representative of clusters described in this paper and shapes of MOFAtools 
predicted allocations. LF1 and LF2 axes represent latent factors as defined by the MOFA 













































Supplementary Table 1. Demographics. Summary clinical data for clustered participants 
(n=34) of the IMOFAP cohort. The cohort is fully described in Skouras et al (for n=57 AP 
patients, including n=3 patients with a symptoms onset at recruitment equal to or greater than 
200 hours and 20 individuals with data available only for one time point). 
  
Number of patients  34 
    Gender   
     Male     55.88% (n=19) 
    Age (years)   
     Median     58.30 
     IQR     23.05 (49.60-72.65) 
    BMI   
     Median     27 
     IQR     7.75 (23-30.75) 
    Source of recruitment   
     A&E     94.12% (n=32) 
     Other     5.88% (n=2) 
    Length of hospital stay (days)   
     Median     5 
     IQR     3 (4-7) 
    Aetiology   
     Gallstones     50.00% (n=17) 
     Alcohol     29.41% (n=10) 
     Other     20.59% (n=7) 
    Charlson index (time point 0)   
     Median     2 
     IQR     3 (1-4) 
    Inhospital mortality (binary)   
     1     5.88% (n=2) 
    Time onset recruitment (hours)   
     Median     22.23 
     IQR     40.86 (11.96-52.81) 
    Alcohol use   
     Current     47.06% (n=16) 
     Previous     8.82% (n=3) 
     None     44.12% (n=15) 
    Smoking   
     Current     29.41% (n=10) 
     Previous     14.71% (n=5) 
     None     55.88% (n=19) 
    Critical care admission (binary)   
     1     8.82% (n=3) 
    APACHE II day 1   
     Median     10 
     IQR     5 (8-13) 
    Previous AP   
     0     61.76% (n=21) 
     1     29.41% (n=10) 
     2     5.88% (n=2) 
     3 or more     2.94% (n=1) 
    CRP (mg/L) (time point 0)   
     Mean     76.21 
     SD     98.86 
 
  
Supplementary table 2. Clustering similarities for 3-cluster solutions. For each time-series-
based method (AUC combined with PCA, Trajectory within PCA-space and dynamic time 
warping), based on 3-cluster solutions, pairwise comparisons were made. Average Jaccard 
index values (averaged over the 3 clusters being compared) are reported in the following table. 
As described for Supplementary figure 2, for a given pairwise comparison, clusters between 
two solutions were matched by maximising the average Jaccard index value. Values are 
displayed for each pairwise comparison and give an idea of the similarity between clustering 
obtained with different methods. Network graphs allowing to compare the different solutions 





AUC+PCA PCA+Trajectory Dynamic time warping 
AUC+PCA / / / 
PCA+Trajectory 0.31 / / 
Dynamic time warping 0.63 0.27 / 
 
Supplementary table 3. Clustering similarities for 5-cluster solutions.  For each time-series 
method (AUC combined with PCA, Trajectory within PCA-space and dynamic time warping), 
based on 5-cluster solutions, comparisons were run using Jaccard index values (computed as 
described in Supplementary table 2). Reported values are averaged Jaccard indexes. Values are 
displayed for each pairwise comparison and gives an idea of overlap between the different 
clustering solutions. Network graphs are available at http://baillielab.net/pancreatitis/networks 




AUC+PCA PCA+Trajectory Dynamic time warping 
AUC+PCA / / / 
PCA+Trajectory 0.24 / / 
Dynamic time warping 0.46 0.21 / 
 
  
Supplementary table 4. Top compound sets. Using glm in R, top 20 pathways (using KEGG 
data for gene, protein and metabolite data and FANTOM5 data for gene and protein data) for 
clusters obtained using the AUC combined with PCA method. FDR-corrected p-values 
obtained are reported along with pathway identifiers and complete names. Input data 
corresponds to time point 0. 
 
Pathway FDR-corrected p-value 
hsa00190 Oxidative phosphorylation <.001 
hsa00230 Purine metabolism <.001 
hsa00240 Pyrimidine metabolism <.001 
hsa00510 N-Glycan biosynthesis <.001 
hsa00970 Aminoacyl-tRNA biosynthesis <.001 
hsa03008 Ribosome biogenesis in eukaryotes <.001 
hsa03010 Ribosome <.001 
hsa03013 RNA transport <.001 
hsa03015 mRNA surveillance pathway <.001 
hsa03018 RNA degradation <.001 
hsa03040 Spliceosome <.001 
hsa04010 MAPK signaling pathway <.001 
hsa04110 Cell cycle <.001 
hsa04120 Ubiquitin mediated proteolysis <.001 
hsa04141 Protein processing in endoplasmic reticulum <.001 
hsa04142 Lysosome <.001 
hsa04144 Endocytosis <.001 
hsa04146 Peroxisome <.001 
hsa04660 T cell receptor signaling pathway <.001 
hsa00280 Valine, leucine and isoleucine degradation <.001 
 
  
Supplementary table 5. Heatmap compounds characteristics. Compounds detailed table for 
heatmap presented in figure 2a. As ordered in figure 2a. Complete gene names were fetched 
using the GeneCards resource and additional information using online resources such as 
HUGO Gene Nomenclature Committee, NCBI EntrezGene, UniProtKB, Ensembl, NCBI 
PubChem, NCBI PubMed and Google Search. Compounds reported in grey italic correspond 
to genes and others to metabolites. 
Heatmap compound Complete name Additional information 
GNAl1 G Protein Subunit Alpha I1 N-acetyl transferase activity 
SPTSSB Serine Palmitoyltransferase 
Small Subunit B 
Tricarboxylic acid cycle(19) 
Citrulline / Sphingolipid biosynthesis 
Dopamine sulfate (2) / Gastrointestinal dopamine 
metabolism(20) 








GGT2 Gamma-Glutamyltransferase 2 g-glutamyl transferase; 
Glutathione homeostasis 
URGCP-MRPS24 URGCP-MRPS24 Readthrough  
ENSG00000262526 / Protein coding 
OR5D16 Olfactory Receptor Family 5 
Subfamily D Member 16 
 
CTAG1A Cancer/Testis Antigen 1A  
MYADML2 Myeloid Associated 
Differentiation Marker Like 2 
 
Ribose /  
CELA2A Chymotrypsin Like Elastase 
Family Member 2A 
Pancreatic elastase-2 
HOXD9 Homeobox D9  
OR6C6 Olfactory Receptor Family 6 
Subfamily C Member 6 
 
UGT1A3 UDP Glucuronosyltransferase 
Family 1 Member A3 
Associated with Gilbert-type 
hyperbilirubinemia(22, 23) 
SLCO1B7 Solute Carrier Organic Anion 
Transporter Family Member 
1B7 (Putative) 
Cysteine-type endopeptidase 
USP17L18 Ubiquitin Specific Peptidase 17-
Like Family Member 18 
Liver-specific organic anion 
transporter; Bile secretion 
DMRTC1 DMRT Like Family C1  
CGB3 Chorionic Gonadotropin Subunit 
Beta 3 
 




PPP1R42 Protein Phosphatase 1 
Regulatory Subunit 42 
 
SLC16A8 Solute Carrier Family 16 
Member 8 
Lactate transporter; Ketone 
body transporter 
KRTAP6-3 Keratin Associated Protein 6-3  
XIRP1 Xin Actin Binding Repeat 
Containing 1 
Muscle-specific actin binding 
protein upregulated during 
muscle injury(25) 
MAP3K6 Mitogen-Activated Protein 
Kinase Kinase Kinase 6 
Apoptosis signaling(26) 
BICDL2 BICD Family Like Cargo 
Adaptor 2 
 
ZBBX Zinc Finger B-Box Domain 
Containing 
 
CFHR3 Complement Factor H Related 3 Heparin-binding; Complement 
regulation 
Inositol 1-phosphate (I1P) / Inositol biosynthesis 




SPEM1 Spermatid Maturation 1  




TRIM48 Tripartite Motif Containing 48 Interferon-g signalling 
(oxidative stress/apoptosis 
signal-reducting kinase 1)(28) 
REG3A Regenerating Family Member 3 
Alpha 
Bactericidal C-type lectin; 
Known as pancreatitis-
associated protein(29) 
PPP1R3A Protein Phosphatase 1 
Regulatory Subunit 3A 
Genetic association with type 2 















Supplementary Table 6. Demographics. Summary clinical data for included participants of 
the KAPVAL cohort (n=312). For a selected number of clinical data and blood measurements, 
summary values for the 312 KAPVAL samples included in the analysis, are reported in the 
table below. 
Number of patients  312 
   
    Gender   
     Male     46.79% (n=146) 
    Age (years)   
     Median     56.00 
     IQR     30.25 (40.75-71.00) 
    Inhospital mortality (binary)   
     1     5.13% (n=16) 
    Critical care admission (binary)   
     1     12.18% (n=38) 
    CRP (mg/L)   
     Mean     47.62 
     SD     79.85 
 
  
Supplementary Table 7. PLS-DA models predictors. List of predictors for each one the four 
PLS-DA models used to allocate KAPVAL individuals to IMOFAP-derived endotypes. 
Metabolomics data was used to build the predictors, hence, all reported variables correspond 
to metabolites. 
Endotype Included predictors 


















N-stearoyltaurine eicosapentaenoate (EPA;20:5n3) 
2-hydroxypalmitate 











4-ethylphenylsulfate oxalate (ethanedioate) 













Supplementary Table 8. Subgroups details. Summary clinical data for clustered participants 
of the IMOFAP cohort (n=34), per cluster, at recruitment. Variables correspond to the ones 
selected for the comparison with ARDS (ordered as in figure 4a), summary values (mean and 
standard deviation) for the 34 IMOFAP samples included in the analysis, at time point 0 
(recruitment), stratified by group, are reported in the table below.  
Number of patients  A (n=13) B (n=10) C (n=5) D (n=6) 
      
    Bicarbonate (mmol/L)      
     Mean 23.85 24.10 24.40 23.50 
     SD 4.39 2.23 0.89 1.64 
    Systolic blood pressure (mmHg)      
     Mean 136.92 133.50 152.20 122.67 
     SD 26.55 22.72 21.46 14.67 
    Platelet count (109/L)      
     Mean 195.25 198.78 314.00 227.33 
     SD 88.27 47.63 74.28 86.06 
    Albumin (g/L)      
     Mean 31.38 35.50 33.80 33.5 
     SD 6.81 4.25 4.32 3.27 
    FiO2 (portion of 1)      
     Mean 0.26 0.21 0.22 0.22 
     SD 0.11 0.01 0.02 0.02 
    Glucose (mg/dL)      
     Mean 8.25 5.99 5.40 7.76 
     SD 5.82 0.65 1.37 3.67 
    BMI (kg/m2)      
     Mean 30.31 25.90 22.4 27.83 
     SD 6.58 6.23 4.45 5.56 
    Age (years)      
     Mean 63.41 57.84 52.86 69.28 
     SD 18.19 13.67 5.14 18.51 
    Sodium (mmol/L)      
     Mean 140.00 137.3 138.20 136.5 
     SD 4.02 2.31 2.05 3.33 
    White cell count (109/L)      
     Mean 11.24 11.32 10.40 14.42 
     SD 5.76 3.93 2.35 6.12 
    Haematocrit (portion of 1)      
     Mean 0.38 0.39 0.36 0.39 
     SD 0.05 0.06 0.07 0.06 
    Temperature (°C)      
     Mean 37.27 37.15 36.22 37.02 
     SD 0.75 0.45 0.75 0.70 
    Bilirubin (umol/L)      
     Mean 30.69 27.10 7.40 39.33 
     SD 20.97 17.80 2.19 35.99 
    Respiratory rate (/min)      
     Mean 21.92 18.00 16.80 16.67 
     SD 6.40 2.05 1.79 1.75 
    Creatinine (umol/L)      
     Mean 99.92 69.80 64.40 70.17 
     SD 47.05 17.23 7.73 15.80 
    Mean arterial pressure (mmHg)      
     Mean 99.67 99.00 113.40 87.17 
     SD 21.10 18.09 12.66 13.38 
    Heart rate (/min)      
     Mean 91.00 78.70 68.00 70.00 
     SD 27.31 10.56 12.41 19.31 
    IL 8 CXCL8 (pg/mL)      
     Mean 129.59 9.47 8.58 11.63 
     SD 244.38 8.41 4.05 9.03 
    IL 6 (pg/mL)      
     Mean 1645.72 126.18 35.07 55.52 
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